Incidence and prevalence of CIDP and the association of diabetes mellitus

Laughlin, Ruple S.; Melton, L. Joseph; Leibson, Cynthia L.; Ransom, Jeanine E.; Dyck, Peter J.

doi:10.1212/wnl.0b013e3181aaea47

Cited by 270 publications

(215 citation statements)

References 30 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…Only one of the 23 CIDP patients (4%) also had DM, whereas 14 of 115 age-and sexmatched controls (12%) had DM. 6 The findings of these studies therefore do not support an increased incidence of DM in patients with CIDP. 6,18 However, it is possible that some CIDP patients were not identified or that some CIDP cases with associated DM, or preclinical DM, were missed.…”

Section: -17mentioning

confidence: 74%

“…6 The findings of these studies therefore do not support an increased incidence of DM in patients with CIDP. 6,18 However, it is possible that some CIDP patients were not identified or that some CIDP cases with associated DM, or preclinical DM, were missed. CIDP may occur with equal frequency in patients with types 1 and 2 DM, 19 presenting a diagnostic challenge: both CIDP and diabetes may result in elevated CSF protein.…”

Section: -17mentioning

confidence: 74%

“…5 The incidence and prevalence of CIDP have been estimated at 1.6/100,000/year to 8.9/100,000, respectively. 6 There are many phenotypic variants of CIDP (Table 1), which suggests that the disorder may not be a discrete entity, but a spectrum of conditions. 7 Elevated levels of cerebrospinal fluid (CSF) protein are present in the majority of patients although normal CSF results do not exclude the diagnosis of CIDP.…”

Section: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (Cmentioning

confidence: 99%

See 2 more Smart Citations

Chronic Inflammatory Demyelinating Polyradiculoneuropathy 101—Pitfalls and Pearls of Diagnosis and Treatment

Beydoun¹,

Brannagan²,

Donofrio³

et al. 2017

US Neurology

View full text Add to dashboard Cite

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), which is caused by demyelination of the peripheral nerves, is characterized by progressive weakness and impaired sensory function in the arms and legs. CIDP is a treatable condition in which early diagnosis is crucial to limit chronic disability. CIDP can mimic other neuropathies and it is important to identify these in order to ensure prompt treatment. Patients with other causes of neuropathy should be suspected of having CIDP if there is rapid progress or proximal weakness. Intravenous immunoglobulin (IVIG), corticosteroids, and plasma exchange are first-line therapies. The IVIG CIDP Efficacy (ICE) trial, the largest trial reported of any CIDP treatment, demonstrated that IVIG therapy reduced disability and functional impairment, as well as improved quality of life. Autoantibodies against membrane proteins of the peripheral nerve axons or the myelin sheath have been reported recently, and an improved understanding of antibody responses in CIDP may enable the development of future targeted therapeutic interventions.

show abstract

Section: -17mentioning

confidence: 74%

Section: -17mentioning

confidence: 74%

Section: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (Cmentioning

confidence: 99%

See 1 more Smart Citation

Chronic Inflammatory Demyelinating Polyradiculoneuropathy 101—Pitfalls and Pearls of Diagnosis and Treatment

Beydoun¹,

Brannagan²,

Donofrio³

et al. 2017

US Neurology

View full text Add to dashboard Cite

show abstract

“…During the 1970s increasingly large series of patients were published, notably by Dyck et al [22] at the Mayo Clinic. It is the most common treatable neuropathy worldwide [4,[23][24][25], with a prevalence ranging from 2.0-3.0 to 8.9 per 100,000 people [26]. In a recently reported epidemiological study, mean age of onset was 57.7 years, prevalence increased with age and reached a maximum in the 70-79-year age group [27].…”

Section: Cidpmentioning

confidence: 99%

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

Immunotherapy has been investigated in a small subset of peripheral neuropathies, including an acute one, Guillain-Barré syndrome, and 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and neuropathy associated with IgM anti-myelin-associated glycoprotein. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis. Either cell-mediated mechanisms or antibody responses to Schwann cell, compact myelin, or nodal antigens are considered to act together in an aberrant immune response to cause damage to peripheral nerves. Immunomodulatory treatments used in these neuropathies aim to act at various steps of this pathogenic process. However, there are many phenotypic variants and, consequently, there is a significant difference in the response to immunotherapy between these neuropathies, as well as a need to improve our knowledge and long-term management of chronic forms.

show abstract

“…2,3 A universally accepted definition of disease does not exist. A variety of clinical and investigational criteria have been proposed and applied in attempts to include the various presentations of CIDP.…”

mentioning

confidence: 99%

Biological Agents for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Stübgen¹

2014

US Neurology

View full text Add to dashboard Cite

Chronic inflammatory demyelinating polyneuropathy (CIDP) denotes a spectrum of acquired, chronically progressive, or recurrent, immunemediated disorders of the peripheral nervous system with variable pathology and pathogenesis. 1 The estimated prevalence may be up to nine per 100,000 Due to the unpredictable efficacy, financial burden, and/or toxicity of 'broad-spectrum' immunomodulatory/-suppressive drugs, a need exists to develop effective and safe therapeutic strategies. 19,20 Research is hindered by the current lack of consensus on appropriate outcome measures and definition of treatment failure, as well as the tendency to study potentially effective therapy exclusively on refractive CIDP patients. 21,22 In order to realize the full potential of any new drug/agent, it may be advisable to identify and exclude from future drug trials any patients with predictably unresponsive (chronically stable and inactive) disease. 20 The future development and application of biomarkers could assist in the selection of effective therapy at initiation and long-term. 23 This review offers an updated summary and analysis of the genetically engineered, biological therapeutic agents considered potentially useful in patients with CIDP. Specific recommendations on management strategies are not proposed, as reviews on this subject have been published. [24][25][26][27][28] Biological therapeutics may rarely induce dysimmune inflammatory neuropathies (discussed elsewhere). 29 T-lymphocytesActivated T-lymphocytes invade peripheral nerve and partake in the pathogenesis of CIDP. 6,7,30 Natalizumab Natalizumab (Tysabri®) is a monoclonal antibody (mAb) targeted at the α4 subunit of α4β1 (VLA4) and α4β7 integrins that are expressed on AbstractChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a term for a group of acquired, immune-mediated inflammatory demyelinating disorders of the peripheral nervous system. Most patients with CIDP respond to 'first-line' therapy with intravenous immunoglobulin (IVIG), plasmapheresis, and/or corticosteroids. 'Conventional' immunosuppressive drugs are of no proven benefit. Biological agents directed at key aspects of the CIDP immunopathogenic pathway have gained increasing attention due to the unpredictable efficacy and overall health risks of non-targeted immunosuppressive drugs. Presently, there exists insufficient clinical experience with biological therapy to allow specific treatment recommendations for CIDP. The challenge remains to identify drug-naïve or treatment-resistant CIDP patients who will most likely respond to targeted immunotherapy.

show abstract

Incidence and prevalence of CIDP and the association of diabetes mellitus

Abstract: Background:The reported prevalence of chronic inflammatory demyelinating polyradiculoneu-

Cited by 270 publications

References 30 publications

Chronic Inflammatory Demyelinating Polyradiculoneuropathy 101—Pitfalls and Pearls of Diagnosis and Treatment

Chronic Inflammatory Demyelinating Polyradiculoneuropathy 101—Pitfalls and Pearls of Diagnosis and Treatment

Immunotherapy in Peripheral Neuropathies

Biological Agents for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Contact Info

Product

Resources

About